Myriad Genetics Inc
$ 5.61
-1.58%
24 Jul - close price
- Market Cap 538,355,000 USD
- Current Price $ 5.61
- High / Low $ 5.76 / 5.58
- Stock P/E N/A
- Book Value 3.57
- EPS -4.34
- Next Earning Report 2026-08-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.08 %
- ROE -0.24 %
- 52 Week High 8.59
- 52 Week Low 3.53
About
Myriad Genetics, Inc., a molecular diagnostics company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company is headquartered in Salt Lake City, Utah.
Analyst Target Price
$6.25
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-05 | 2026-02-23 | 2025-11-03 | 2025-08-05 | 2025-05-06 | 2025-02-24 | 2024-11-07 | 2024-08-06 | 2024-05-07 | 2024-02-27 | 2023-11-06 | 2023-08-03 |
| Reported EPS | -0.09 | 0.04 | -0.29 | 0.05 | -0.03 | 0.03 | 0.06 | 0.05 | -0.01 | 0.04 | -0.03 | -0.08 |
| Estimated EPS | -0.07 | -0.0172 | -0.01 | -0.01 | -0.05 | 0.0303 | 0.02 | -0.01 | -0.11 | 0.01 | -0.08 | -0.09 |
| Surprise | -0.02 | 0.0572 | -0.28 | 0.06 | 0.02 | -0.0003 | 0.04 | 0.06 | 0.1 | 0.03 | 0.05 | 0.01 |
| Surprise Percentage | -28.5714% | 332.5581% | -2800% | 600% | 40% | -0.9901% | 200% | 600% | 90.9091% | 300% | 62.5% | 11.1111% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-04 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.08 |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | |
|---|---|
| Payment Date | None |
| Amount | $1.75 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MYGN
2026-07-23 17:39:57
Myriad Genetics (NASDAQ: MYGN) stock is influenced by its revenue growth in precision oncology and plans to improve profitability. The company has shown a low double-digit percentage increase in annual revenue, reaching approximately $700 million, driven by oncology and women’s health testing. While still reporting a net loss, it has significantly reduced it from $90 million to $50 million, indicating progress in cost control and operational efficiency.
2026-07-23 13:11:03
Myriad Genetics (NASDAQ: MYGN) will release its second-quarter 2026 financial results after market close on Thursday, July 30, 2026. This will be followed by an earnings conference call at 4:30 p.m. ET, during which management will provide a financial overview and business update. A live webcast and archived replay will be available on the company's Investor Relations website.
2026-07-22 11:10:46
Myriad Genetics has launched FirstGene® Multiple Prenatal Screen, a new diagnostic test that simultaneously performs four prenatal genetic screens from a single blood draw as early as eight weeks gestation. This innovative test aims to streamline the prenatal screening process, providing clinicians with comprehensive insights into fetal chromosome conditions, fetal single-gene conditions, patient carrier status, and fetal RhD compatibility. The company claims the screen has high analytical sensitivity and specificity, with results expected in about 10 days.
2026-07-21 15:50:00
Myriad Genetics has launched FirstGene Multiple Prenatal Screen, a new laboratory test that performs four prenatal genetic screens from a single maternal blood draw as early as eight weeks of pregnancy. This innovative test combines fetal chromosome, fetal single-gene, patient carrier, and fetal RhD screenings into one comprehensive report, with results available in approximately 10 days. The FirstGene screen aims to streamline prenatal genetic testing by consolidating multiple guideline-supported assessments without requiring a partner sample.
2026-07-21 14:39:30
Myriad Genetics has announced the full commercial launch of its FirstGene Multiple Prenatal Screen, a new laboratory test capable of performing four prenatal genetic screens from a single blood sample as early as eight weeks gestation. The test integrates fetal chromosome, fetal single-gene, patient carrier, and fetal RhD screenings, providing results in approximately 10 days. This comprehensive approach aims to streamline prenatal care and offer clinicians more complete information earlier in pregnancy.
2026-07-21 12:39:30
Myriad Genetics has launched FirstGene®, a new prenatal screen that simultaneously performs four prenatal genetic screens from a single blood draw as early as eight weeks gestation. This test offers fetal chromosome screening, fetal single-gene screening, patient carrier screening, and fetal RhD screening, with results expected in approximately 10 days. The company aims to streamline prenatal care and provide comprehensive insights earlier in pregnancy, complementing its existing portfolio of prenatal screening products.
